← Back

Wire · opportunities

Alnylam Pharmaceuticals (ALNY) Wins FDA Approval in Myasthenia Gravis With Seventh RNAi Drug

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

Alnylam Pharmaceuticals and Regeneron won FDA approval for Livsayis, the first RNAi-based therapy for generalized myasthenia gravis, marking Alnylam's seventh FDA-approved RNA interference drug in around nine years.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new FDA-cleared RNA interference therapy for a rare neuromuscular disease opening a revenue stream beyond previous drug franchises. Watch Regeneron's sales reports closely for early signs of market takeoff and royalty growth.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechrna-interferencefda-approvalmyasthenia-gravisbiotechalnylam-pharmaceuticals